Literature DB >> 21585608

A new modified concomitant therapy for Helicobacter pylori eradication in Turkey.

Ahmet Burak Toros1, Ali Tüzün Ince, Besir Kesici, Mustafa Saglam, Zulfikar Polat, Ahmet Uygun.   

Abstract

BACKGROUND: Helicobacter pylori eradication rates have tended to decrease recently, mostly due to antibiotic resistance. In the present study, our aim was to determine Hp eradication rate with the LAC plus tid metronidazole regimen and the secondary objective of this study was to identify an effective regimen for our population.
METHODS: Eighty-four Hp-positive patients with non-ulcer dyspepsia were assigned into the same group. Patients were administered the classical LAC protocole (lansoprazole 30 mg bid, amoxicillin 1 g bid and claritromycin 500 mg bid for 14 days) plus metronidazole 500 mg tid for 14 days. Gastroscopy and histopathological assessment were performed before enrollment and C(14) urea breath test and stool antigen test were performed 6 weeks after treatment.
RESULTS: All 84 patients completed the study. No patient left the study because of drug side effect. Total eradication rate was 75% (63/84).
CONCLUSION: Although LAC plus tid metronidazole regimen achieved a much better eradication rate compared with the standard LAC regimen; this is the first study that has a relatively low success with a concomitant therapy. So in areas of high resistance like Turkey, one cannot expect a high success with any clarithromycin containing regimen and those should be avoided.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21585608     DOI: 10.1111/j.1523-5378.2011.00823.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  7 in total

1.  Challenging the dogma: a randomized trial of standard vs. half-dose concomitant nonbismuth quadruple therapy for Helicobacter pylori infection.

Authors:  Ala I Sharara; Fayez S Sarkis; Mustapha M El-Halabi; Ahmad Malli; Nabil M Mansour; Cecilio Azar; Mohamad A Eloubeidi; Fadi H Mourad; Kassem Barada; Ismail Sukkarieh
Journal:  United European Gastroenterol J       Date:  2014-06       Impact factor: 4.623

Review 2.  Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance.

Authors:  Javier Molina-Infante; Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

3.  How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery?

Authors:  Rute M Cerqueira; Manuel R Correia; Hélder Vilar; M Conceição Manso
Journal:  Obes Surg       Date:  2016-06       Impact factor: 4.129

4.  Sequential therapy versus standard triple therapy in Helicobacter pylori eradication in a high clarithromycin resistance setting.

Authors:  Can Dolapcioglu; Aysun Koc-Yesiltoprak; Emel Ahishali; Aziz Kural; Hatice Dolapcioglu; Aliye Soylu; Resat Dabak
Journal:  Int J Clin Exp Med       Date:  2014-08-15

5.  Management of Helicobacter Pylori Infection and Effectiveness Rates in Daily Clinical Practice in Spain: 2010-2019.

Authors:  Inés Ariño Pérez; Samuel J Martínez-Domínguez; Enrique Alfaro Almajano; Patricia Carrera-Lasfuentes; Ángel Lanas
Journal:  Antibiotics (Basel)       Date:  2022-05-20

6.  Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori.

Authors:  Javier P Gisbert; Xavier Calvet
Journal:  Clin Exp Gastroenterol       Date:  2012-03-13

Review 7.  Efficiency of Diagnostic Testing for Helicobacter pylori Infections-A Systematic Review.

Authors:  Paula Rojas García; Simon van der Pol; Antoinette D I van Asselt; Maarten Postma; Roberto Rodríguez-Ibeas; Carmelo A Juárez-Castelló; Marino González; Fernando Antoñanzas
Journal:  Antibiotics (Basel)       Date:  2021-01-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.